Biologics Spine Top Stories Bone Biologics Appoints Phillip T. Meikle to its Board of Directors byJosh SandbergOctober 21, 2024
Financial Spine Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds byTim AllenAugust 2, 2024
Financial Bone Biologics Announces Closing of $2.0 Million Public Offering byJosh SandbergMarch 6, 2024
Financial Bone Biologics Announces Pricing of $2.0 Million Public Offering byJosh SandbergMarch 4, 2024
Biologics Spine Bone Biologics Reports Progress With NB1 Clinical Program byJosh SandbergMarch 1, 2024
Biologics Financial Spine Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors byJosh SandbergJanuary 11, 2024
Financial Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules byJosh SandbergNovember 20, 2023
Financial Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules byJosh SandbergNovember 17, 2023
Financial Bone Biologics Prices $5.0 Million Underwritten Public Offering byJosh SandbergJune 15, 2023
